First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

• المؤلفون الرئيسيون: James Chih Hsin Yang, Jin Hyoung Kang, Tony Mok, Myung Ju Ahn, Vichien Srimuninnimit, Chia Chi Lin, Dong Wan Kim, Chun Ming Tsai, Helen Barraclough, Sedat Altug, Mauro Orlando, Keunchil Park
• مؤلفون آخرون: National Taiwan University Hospital
• التنسيق: مقال
• منشور في: 2018
• الموضوعات: Biochemistry, Genetics and Molecular Biology; Medicine
• الوصول للمادة أونلاين: https://repository.li.mahidol.ac.th/handle/123456789/33507

Background In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved progression-free survival (PFS) versus carboplatin-paclitaxel in clinically selected lung cancer patients. The primary objective of this study was to assess the PFS of pemetrexed-cisplatin (PC) followed by gefitinib maintena...